Clinical Research

Jasper Therapeutics Inc.

Address
2200 Bridge Parkway Suite 102

Sponsor Overview

assignment
4
sponsored trials
science
2
molecules
location_city
14
research centres
public
1
country
person_search
17
investigators

Specializations

Chronic Urticaria and Inducible Urticaria

Jasper Therapeutics Inc. focuses on clinical research in chronic urticaria, including chronic spontaneous urticaria, chronic inducible urticaria, and related forms such as cold urticaria and symptomatic dermographism.

  • Chronic Spontaneous Urticaria
  • Chronic Inducible Urticaria
  • Cold Urticaria
  • Symptomatic Dermographism

The sponsor’s studies address persistent wheals, itching, and antihistamine-refractory symptoms in adult populations.

Allergic Asthma

The company also funds research in allergic asthma, reflecting interest in airway inflammation and allergic disease control.

  • Allergic Asthma
  • Asthma Symptom Control
  • Allergic Airway Disease

This area extends the sponsor’s therapeutic focus beyond skin disorders to respiratory allergy-related conditions.

Briquilimab Clinical Development

Across its trial portfolio, Jasper Therapeutics is centered on briquilimab in immunology and allergic disease, with research examining safety, tolerability, and clinical activity in symptomatic patients.

  • Briquilimab
  • Immunology
  • Allergic Disease
  • Mast Cell-Related Disorders

The sponsor’s active studies are concentrated in the United States and involve multiple collaborating research sites.

Sponsored Trials

Trial Name Country Status
Evaluation of Briquilimab and Adrenaline Tartrate in Chronic Inducible Urticaria Unresponsive to H1-Antihistamines in AdultsGermany GermanyNot Recruiting
Evaluation of Briquilimab Safety and Pharmacokinetics in Adults with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines or OmalizumabGermany GermanyNot Recruiting
Evaluation of Briquilimab's Safety and Efficacy in a Double-Blind, Placebo-Controlled Study for Patients with Allergic AsthmaGermany GermanyNot Recruiting
Evaluation of Long-Term Safety and Clinical Activity of Briquilimab in Patients with Chronic Urticaria: An Open-Label Extension StudyGermany GermanyNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 2 total (50% not shared with other sponsors)

This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
50%
Return partnership rate
7 of 14 sites collaborated multiple times

This sponsor has worked with 14 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Immune System Diseases3 trials
    322 other sponsors
  • 2.
    Skin and Connective Tissue Diseases3 trials
    247 other sponsors
  • 3.
    Respiratory Tract Diseases1 trial
    277 other sponsors

Partnered Research Centres

14 centres
location_city
assignment518
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz
Address
Langenbeckstrasse 1, Oberstadt, 55131 Mainz
Learn morearrow_forward
location_city
assignment1047
Charite Universitaetsmedizin Berlin KöR
Address
Hindenburgdamm 30, Lichterfelde, 12203 Berlin
Learn morearrow_forward
location_city
assignment38
Elbe Kliniken Stade-Buxtehude gGmbH
Address
Am Krankenhaus 1, 21614 Buxtehude
Learn morearrow_forward
location_city
assignment620
Goethe University Frankfurt
Address
Theodor-Stern-Kai 7, 60590 Frankfurt
Learn morearrow_forward
location_city
assignment23
Gynaekologisches Zentrum Bonn
Address
Friedensplatz 16, Zentrum, 53111 Bonn
Learn morearrow_forward
location_city
assignment84
IKF Pneumologie GmbH & Co. KG
Address
Haifa-Allee 24, Bretzenheim, 55128 Frankfurt
Learn morearrow_forward
Page 1 of 3

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Jasper Therapeutics Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.